

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

*(Use as many sheets as necessary)*

Sheet	1	of	2
-------	---	----	---

Complete if Known **40240367**

Application Number	Not Yet Assigned
Filing Date	Herewith
First Named Inventor	Hurwitz, et.al.
Art Unit	Unknown 1648
Examiner Name	Unknown Chen, S.B.
Attorney Docket Number	SJ-02-0015A

[illegible][illegible]

/Stacy B. Chen/

08/28/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/540367
		Filing Date	Herewith
		First Named Inventor	Hurwitz, et.al.
		Art Unit	Unknown
		Examiner Name	Unknown
Sheet 2	of 2	Attorney Docket Number	SJ-02-0015A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/SBC/	C1	HURWITZ, J.L., et al; "Intranasal Sendai virus vaccine protects African green monkeys from infection with human parainfluenza virus-type one"; Vaccine 15:533-540 (1997)	
/SBC/	C2	GORMAN, W.L., et al; "The Hemagglutinin-Neuraminidase Glycoproteins of Human Parainfluenza Virus Type 1 and Sendai Virus have high structure-function similarity with limited Antigenic cross-reactivity"; Virology 175:211-221 (1990)	
/SBC/	C3	SANGSTER, M., et al; "Human Parainfluenza Type 1 Immunization of Infant Mice Protects from Subsequent Sendai Virus Infection"; Virology 212:13-19 (1995)	
/SBC/	C4	SKIADOPOULOS, M.H., et al; "Sendai Virus, a Murine Parainfluenza Virus Type 1, Replicates to a Level Similar to Human PIV1 in the Upper and Lower Respiratory Tract of African Green Monkey and Chimpanzees"; Virology 297:153-160 (2002)	
/SBC/	C5	VAN WYKE COELINGH, K.L., et al.; "Attenuation of Bovine Parainfluenza Virus Type 3 in Nonhuman Primates and Its Ability to Confer Immunity to Human Parainfluenza Virus Type 3 Challenge"; J Inf Dis 157:655-662 (1988)	
/SBC/	C6	WANG, X-L, et al.; "A Protease Activation Mutant, MVCES1, as a Safe and Potent Live Vaccine Derived from Currently Prevailing Sendai Virus"; J Viro 68:3369-3373 (1994)	

Examiner Signature	/Stacy B. Chen/	Date Considered	08/28/2007
--------------------	-----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.